What does Certipharm do?

Certipharm is filed with the CBE under the catch-all “Overige zakelijke dienstverlening”, a code that says little about what the company actually does. Private Limited, started on 22 September 2020, 1 establishment.

What is the address of Certipharm?

The registered office of Certipharm is located at Molenbaan 50, 2290 Vorselaar.

Is Certipharm still active?

Yes. According to the CBE (29 October 2026) Certipharm is active, legal situation “Normale toestand”, started on 22 September 2020.

Is Certipharm registered on Peppol?

Yes, Certipharm is registered on the Peppol network with ID 0208:0754702164.

What is the enterprise number of Certipharm?

The enterprise number of Certipharm is BE0754702164.

When was Certipharm founded?

Certipharm was founded on 22 September 2020.

Who are the directors of Certipharm?

According to the 2025 annual accounts, the directors of Certipharm are: Frédéric Broechoven.

Is Certipharm a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 22 September 2020; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Certipharm make in 2025?

Certipharm posted a profit after taxes of € 91,689 in financial year 2025.

What is the revenue of Certipharm?

As a small company, Certipharm is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 124,569.

Certipharm (Private Limited) - Vorselaar - BE0754702164

Dossier Certipharm, printed on 29 October 2026 from databakkes.be/en/0754702164/certipharm. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Certipharm from Vorselaar, company number BE0754702164, closed financial year 2025 with a result of € 91,689 after tax. For that financial year Certipharm recorded a gross margin of € 124,569 and equity of € 102,793. Compared with financial year 2024, the result moved from € 59,104 to € 91,689. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 14, 2026.

What it is worth Growing

€ 102,793

▲ 68% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 91,689

▲ 55% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 136,612

▲ 191% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 50,000 paid out

55 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Vehicles and equipment

€ 1,778

▲ 24% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 127

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 3,593

▼ 10% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 105,362 Gross margin 2022: € 105,362 First fiscal year in the series	€ 139,092 Gross margin 2023: € 139,092 ▲ 32% vs 2022 (€ 105,362) Favourable step	€ 85,612 Gross margin 2024: € 85,612 ▼ 38% vs 2023 (€ 139,092) Unfavourable step	€ 124,569 Gross margin 2025: € 124,569 ▲ 46% vs 2024 (€ 85,612) Favourable step	▲ 46%
Profit after taxes	€ 77,028 Profit after taxes 2022: € 77,028 First fiscal year in the series	€ 104,348 Profit after taxes 2023: € 104,348 ▲ 35% vs 2022 (€ 77,028) Favourable step	€ 59,104 Profit after taxes 2024: € 59,104 ▼ 43% vs 2023 (€ 104,348) Unfavourable step	€ 91,689 Profit after taxes 2025: € 91,689 ▲ 55% vs 2024 (€ 59,104) Favourable step	▲ 55%
Equity	€ 192,580 Equity 2022: € 192,580 First fiscal year in the series	€ 295,929 Equity 2023: € 295,929 ▲ 54% vs 2022 (€ 192,580) Favourable step	€ 61,104 Equity 2024: € 61,104 ▼ 79% vs 2023 (€ 295,929) Unfavourable step	€ 102,793 Equity 2025: € 102,793 ▲ 68% vs 2024 (€ 61,104) Favourable step	▲ 68%
Total debts	€ 18,643 Total debts 2022: € 18,643 First fiscal year in the series	€ 21,557 Total debts 2023: € 21,557 ▲ 16% vs 2022 (€ 18,643) Unfavourable step	€ 4,166 Total debts 2024: € 4,166 ▼ 81% vs 2023 (€ 21,557) Favourable step	€ 54,580 Total debts 2025: € 54,580 ▲ € 50,413 vs 2024 (€ 4,166) Unfavourable step	▲ € 50,413
Cash	€ 190,528 Cash 2022: € 190,528 First fiscal year in the series	€ 270,640 Cash 2023: € 270,640 ▲ 42% vs 2022 (€ 190,528) Favourable step	€ 46,976 Cash 2024: € 46,976 ▼ 83% vs 2023 (€ 270,640) Unfavourable step	€ 136,612 Cash 2025: € 136,612 ▲ 191% vs 2024 (€ 46,976) Favourable step	▲ 191%
Retained profit	€ 190,580 Retained profit 2022: € 190,580 First fiscal year in the series	€ 293,929 Retained profit 2023: € 293,929 ▲ 54% vs 2022 (€ 190,580) Favourable step	€ 59,104 Retained profit 2024: € 59,104 ▼ 80% vs 2023 (€ 293,929) Unfavourable step	€ 100,793 Retained profit 2025: € 100,793 ▲ 71% vs 2024 (€ 59,104) Favourable step	▲ 71%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 1,000 Dividend 2023: € 1,000 Unchanged (€ 0) Unchanged	€ 293,929 Dividend 2024: € 293,929 ▲ € 292,929 vs 2023 (€ 1,000) Unchanged	€ 50,000 Dividend 2025: € 50,000 ▼ 83% vs 2024 (€ 293,929) Unchanged	▼ 83%
Balance sheet total	€ 211,223 Balance sheet total 2022: € 211,223 First fiscal year in the series	€ 317,485 Balance sheet total 2023: € 317,485 ▲ 50% vs 2022 (€ 211,223) Unchanged	€ 65,270 Balance sheet total 2024: € 65,270 ▼ 79% vs 2023 (€ 317,485) Unchanged	€ 157,372 Balance sheet total 2025: € 157,372 ▲ 141% vs 2024 (€ 65,270) Unchanged	▲ 141%

Key figures of Certipharm, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Certipharm?

What happened at Certipharm in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 14, 2026 New annual accounts for financial year 2025: profit of € 91,689 (▲ 55% vs 2024). filed late Source: NBB ↗
Sep 22, 2020 New establishment in Vorselaar. KBO
Sep 22, 2020 Start of the company according to the CBE. KBO

In short

From € 77,028 profit in 2022 to € 91,689 profit in 2025.

Paid € 106,207 in corporate taxes since 2022.

Best year ever: 2023, with € 104,348 profit.

Paid out € 344,929 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Frédéric Broechoven

Certipharm

Behind Certipharm is Frédéric Broechoven.

Directors

According to the 2025 annual accounts

Frédéric Broechoven

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Molenbaan 50

2290 Vorselaar

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0754.702.164
VAT number: BE 0754.702.164
Registered office: Molenbaan 50, 2290 Vorselaar
Names & denominations: Certipharm
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 22 September 2020
Peppol: Active · Active since 2 Oct 2025
Activities · NACE: Overige zakelijke dienstverlening, neg

View on CBE Public ↗ Annual accounts (NBB) ↗